The total operating expenses increased during the second quarter to $96 million, which can be attributed to additional costs associated with higher revenue and infrastructure expansion. The company attributes its success to the product line for the lateral lumbar interobody fusion approach, MaXcess split blade retractor system and other products associated with the Maximum Access Surgery platform.
Despite the rise in revenue, there was a slight decline in net income attributable to NuVasive, from $6.7 million during the second quarter of 2010 to $5.3 million in 2011.
Read the release about the financial report for NuVasive.
Related Articles on Orthopedic Device Companies:
MiMedx Reports $1.9M 2Q Revenue, 6-Fold Increase
Stryker Reports $2.05B 2Q Net Sales, 12% Increase
Biomet Reports $715.2M in 4Q Net Sales, 2% Increase
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.